ROGER STÜPP
![](http://www.evecon.com.br/bandeiras/eua.gif)
Paul C. Bucy Professor of Neurological Surgery
Professor of Medicine (Hematology/Oncology) and Neurology,
Northwestern University Feinberg School of Medicine;
Co-Director, Northwestern Medicine Lou & Gene Malnati Brain
Tumor Institute; Associate Director for Strategic Initiatives, Robert
H. Lurie Comprehensive Cancer Center of Northwestern
University, Chicago, IL
Dr. Roger Stupp is an internationally renowned medical oncologist and a leading authority on primary and metastatic brain cancer who has established temozolomide and radiation in 2004, and Tumor Treating Fields in 2016 as the first line treatment of glioblastoma. Jointly with Monika Hegi, PhD (University of Lausanne) they identified MGMT as a predictive factor for benefit from temozolomide. More recent work
focuses on opening the blood-brain barrier with ultrasound (with Adam Sonabend, MD) allowing the use of novel cancer drugs early in the disease course. Surrounded by a large team of top-notch researchers of the Malnati Brain Tumor Institute at Northwestern University in Chicago he and team are investigating are pushing the boundaries by combining latest diagnostic and therapeutic technologies, novel drugs and compounds and innovative trial designs to improve outcome for patients suffering from brain tumors.
Professor of Medicine (Hematology/Oncology) and Neurology,
Northwestern University Feinberg School of Medicine;
Co-Director, Northwestern Medicine Lou & Gene Malnati Brain
Tumor Institute; Associate Director for Strategic Initiatives, Robert
H. Lurie Comprehensive Cancer Center of Northwestern
University, Chicago, IL
Dr. Roger Stupp is an internationally renowned medical oncologist and a leading authority on primary and metastatic brain cancer who has established temozolomide and radiation in 2004, and Tumor Treating Fields in 2016 as the first line treatment of glioblastoma. Jointly with Monika Hegi, PhD (University of Lausanne) they identified MGMT as a predictive factor for benefit from temozolomide. More recent work
focuses on opening the blood-brain barrier with ultrasound (with Adam Sonabend, MD) allowing the use of novel cancer drugs early in the disease course. Surrounded by a large team of top-notch researchers of the Malnati Brain Tumor Institute at Northwestern University in Chicago he and team are investigating are pushing the boundaries by combining latest diagnostic and therapeutic technologies, novel drugs and compounds and innovative trial designs to improve outcome for patients suffering from brain tumors.
Confira a agenda de atividades
22 DE MARÇO | SEXTA-FEIRA
Room 1
13:30-15:30
SESSION 2: GLIOMAS
Radiomics to predict MGMT, IDH mutations and EGFR amplifications
Understanding the radiotherapy effects in glioma oncogenesis
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Challenges of insular gliomas surgery
Beyond boundaries: exploring the impact of supratotal resection on diffuse gliomas
The role of re-irradiation for recurrent adult-type diffuse gliomas
Update on antiepileptic drugs use for glioma's patients
Discussion
Moderator: Daniel Andrade Gripp (SP)
Moderator: Iuri Santana Neville Ribeiro (SP)
Moderator: Fabiana Spillari Viola (RS)
Radiomics to predict MGMT, IDH mutations and EGFR amplifications
Speaker: Rajan Jain (Estados Unidos)
Understanding the radiotherapy effects in glioma oncogenesis
Speaker: Fabio Ynoe de Moraes (Canadá)
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Speaker: Roger Stüpp (Estados Unidos)
Challenges of insular gliomas surgery
Speaker: Frederick F. Lang (Estados Unidos)
Beyond boundaries: exploring the impact of supratotal resection on diffuse gliomas
Speaker: Lorenzo Bello (Itália)
The role of re-irradiation for recurrent adult-type diffuse gliomas
Speaker: Andre Tsin Chih Chen (SP)
Update on antiepileptic drugs use for glioma's patients
Speaker: Gabriel Novaes de Rezende Batistella (SP)
Discussion
15:50-17:30
PLENARY SESSION 2
Awake glioma surgery: technical evolutions and nuances
The role of liquid biopsy in neuro-oncology
How can NGS affect prognosis and treatment for diffuse gliomas?
Radiogenomics in gliomas
SNO Institutional Presentation
Moderator: Rodrigo Ferrari Fernandes Naufal (SP)
Moderator: Daniel Marques (DF)
Moderator: José Marcus Rotta (SP)
Awake glioma surgery: technical evolutions and nuances
Speaker: Lorenzo Bello (Itália)
The role of liquid biopsy in neuro-oncology
Speaker: Francisco Martínez Ricarte (Espanha)
How can NGS affect prognosis and treatment for diffuse gliomas?
Speaker: Roger Stüpp (Estados Unidos)
Radiogenomics in gliomas
Speaker: Rajan Jain (Estados Unidos)
SNO Institutional Presentation
Speaker: Chas Haynes (Estados Unidos)
23 DE MARÇO | SÁBADO
Room 1
10:50-12:00
PLENARY SESSION 3
Opening Session
Tumor Treating Fields: current role and future directions
Vaccines and IDHwt gliomas: prospects on the horizon
DNA methilation profiling as a model for precision diagnosis in neurooncology
Moderator: Guilherme Carvalhal Ribas (SP)
Moderator: Cleiton Formentin (SP)
Moderator: Roberto Abramoff (SP)
Opening Session
Tumor Treating Fields: current role and future directions
Speaker: Roger Stüpp (Estados Unidos)
Vaccines and IDHwt gliomas: prospects on the horizon
Speaker: Vinay K. Puduvalli (Estados Unidos)
DNA methilation profiling as a model for precision diagnosis in neurooncology
Speaker: Martha Quezado (Estados Unidos)